Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. (NASDAQ: AXGN) is a leading medical products company specializing in the science, development, and commercialization of technologies for peripheral nerve repair and regeneration. The company's core mission is to restore peripheral nerve function and improve the quality of life for patients suffering from traumatic injuries or surgical procedures that impact nerve function and sensation.
Axogen's innovative product portfolio includes:
- Avance® Nerve Graft: The first and only commercially available allograft for bridging nerve discontinuities.
- Axoguard® Nerve Connector: A coaptation aid designed for the close approximation of severed nerves.
- Axoguard® Nerve Protector: A product that shields nerves during the healing process.
- Axoguard® Nerve Cap: A surgical implant to isolate and protect a peripheral nerve end, minimizing painful neuroma development.
- Axoguard HA+ Nerve Protector: A next-gen nerve protection device designed to provide both short- and long-term protection for peripheral nerve injuries.
- Avive® Soft Tissue Membrane: A biologically active product aiding in nerve healing.
- Axotouch® Two-Point Discriminator: An assessment tool for measuring the innervation density of skin surface areas.
Axogen's products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. The company continues to expand its global presence and partnerships, ensuring that healthcare providers and surgeons have access to clinically and economically effective nerve repair solutions.
Recent achievements include the launch of the Axoguard HA+ Nerve Protector, which provides enhanced nerve gliding and protection for a wide range of peripheral nerve injuries. The company reported strong performance in Q4 2023, with an expected annual revenue growth of 11% to 14% and anticipated gross margins between 76% and 79%.
For more information, visit www.axogeninc.com.
Axogen, a leader in surgical solutions for peripheral nerve damage, will participate in the 76th Annual Meeting of the American Society for Surgery of the Hand (ASSH) from September 30-October 2, 2021 in San Francisco. The company will host a symposium on October 1, featuring an expert panel discussing the impact of Axogen technologies on nerve repair practices. Attendees can engage with Axogen scientists and explore innovative surgical techniques at Booth #950. Axogen will also support educational initiatives and offer travel scholarships for attendees.
Axogen announced the completion of subject follow-up for its pivotal RECON Clinical Study, supporting the Biologics License Application (BLA) for Avance® Nerve Graft. The study met its enrollment target of 220 subjects in July 2020 and is on track for a top-line data read-out in Q2 2022, followed by BLA submission in 2023. The RECON study aims to provide Level 1 clinical data, comparing Avance Nerve Graft to manufactured conduits in digital nerve injuries, focusing on recovery of sensation and quality of life outcomes.
Axogen, Inc. (NASDAQ: AXGN) reported a strong second quarter for 2021, with net revenue of $33.6 million, a 52% increase year-over-year. The company achieved a gross margin of 78.9%, boosted by a recovery in sales despite a $1.4 million one-time charge. While the net loss was $7.9 million ($0.19 per share), this showed improvement compared to the prior year. Additionally, Axogen updated its 2021 revenue guidance to a range of $134.5 million to $137.5 million, enhancing investor confidence in long-term growth.
Axogen, Inc. (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerves, announced that CEO Karen Zaderej will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 1:00 p.m. ET. The event will be available for live streaming on Axogen’s Investors page, with a replay accessible for 90 days. Axogen specializes in technologies for nerve regeneration and repair, offering products like Avance® Nerve Graft and Axoguard Nerve Connector® to restore peripheral nerve function, crucial after injuries or surgeries affecting the nervous system.
Axogen, Inc. (NASDAQ: AXGN) has appointed John H. Johnson to its Board of Directors as of July 19, 2021. Johnson brings over 30 years of biopharma experience from senior roles at major companies including Johnson & Johnson and Eli Lilly. He will contribute to both the Governance, Nominating and Sustainability Committee and the Science and Technology Committee. CEO Karen Zaderej highlights Johnson's expertise in pipeline strategy and commercial execution as a significant asset for the company’s ongoing commitment to innovation in peripheral nerve repair.
Axogen, Inc. (NASDAQ: AXGN) announced it will report Q2 2021 financial results on August 4, 2021, after market close. Management will host a conference call at 4:30 p.m. ET. Interested investors can participate via phone or listen online through Axogen's website. The company specializes in surgical solutions for peripheral nerve repair, offering products like Avance Nerve Graft and Axoguard Nerve Connector. Axogen aims to improve patient outcomes following peripheral nerve injuries.
Axogen, Inc. (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerve damage, announced presentations by CEO Karen Zaderej and CFO Peter Mariani at two investor conferences. They will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 11:30 a.m. ET, and the JMP Securities Life Sciences Conference on June 16, 2021, at 12:30 p.m. ET. Both events will be webcast live, with replays available on the Axogen Investors page for 90 days. Axogen focuses on the development and commercialization of technologies for peripheral nerve regeneration.
Axogen, a leader in surgical solutions for peripheral nerve repair, announced that Peter J. Mariani, CFO, will present at the Canaccord Genuity Musculoskeletal Conference on May 20, 2021, at 11:00 a.m. ET. The presentation will be accessible via live webcast on the company’s investor page. Axogen specializes in technologies that aid in the regeneration and repair of peripheral nerves, aiming to restore nerve function and quality of life for patients affected by nerve damage. Its product portfolio includes several innovative solutions such as Avance® Nerve Graft and Axoguard series.
Axogen, Inc. (NASDAQ: AXGN) reported a 28% increase in net revenue for Q1 2021, totaling $31.0 million compared to $24.3 million in Q1 2020. The gross margin improved to 83.3% from 80.1% year-over-year. Despite a net loss of $6.7 million or $0.16 per share, this was an improvement over the previous year’s loss of $8.2 million. The company ended Q1 2021 with $97.2 million in cash and investments. Axogen anticipates full-year 2021 revenue to be between $133 million and $136 million.
Axogen, Inc. (NASDAQ: AXGN) will announce its first quarter 2021 financial results on May 5, 2021, after market close. The company's management will host a conference call and webcast at 4:30 p.m. ET to discuss the results. Interested investors can participate via phone or listen live on Axogen's website. The company focuses on developing innovative surgical solutions for peripheral nerve repair, including products like Avance® Nerve Graft and Axoguard Nerve Connector®. These offerings aim to restore nerve function and improve patient quality of life.
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
What is Axogen, Inc. focused on?
What are some key products offered by Axogen?
In which markets are Axogen's products available?
What recent product did Axogen launch?
What is the Avance® Nerve Graft?
How did Axogen perform financially in Q4 2023?
What does the Axoguard® Nerve Cap do?
What is the function of the Axotouch® Two-Point Discriminator?
Who is the current CEO of Axogen?
Where can I find more information about Axogen?
